Biochemia Medica最新文献_第2页

YKL-40 as a biomarker in various inflammatory diseases: A review YKL-40 作为各种炎症性疾病的生物标记物：综述

IF 3.3 3区医学

Biochemia Medica Pub Date : 2023-12-19 DOI: 10.11613/bm.2024.010502

Nina Blazevic, Nina Blazevic, Dunja Rogic, Stipe Pelajic, Marijana Miler, Goran Glavcic, Valentina Ratkajec, Nikolina Vrkljan, Dejan Bakula, Davor Hrabar, Tajana Pavic

引用次数: 0

Challenges of providing biochemistry results in a patient with Evans syndrome 为埃文斯综合征患者提供生化结果的挑战

IF 3.3 3区医学

Biochemia Medica Pub Date : 2023-12-19 DOI: 10.11613/bm.2024.011001

Natividad Rico Ríos, Natividad Rico Ríos, Alison Bransfield, Caroline M Joyce, Mary R Cahill, Michelle O’Shaughnessy, Seán J. Costelloe

引用次数: 0

Determination of cystatin C reference interval for children in Croatia 确定克罗地亚儿童胱抑素 C 参考区间

IF 3.3 3区医学

Biochemia Medica Pub Date : 2023-12-19 DOI: 10.11613/bm.2024.010702

Vlasta Cigula Kurajica, Vlasta Cigula Kurajica, Željka Vogrinc, Ana Turčić, Slobodan Galić

引用次数: 0

Point of care testing in Croatia: a survey of the Working group for point of care testing of the Croatian society of medical biochemistry and laboratory medicine 克罗地亚的护理点检测：克罗地亚医学生物化学和实验室医学学会护理点检测工作组的调查

IF 3.3 3区医学

Biochemia Medica Pub Date : 2023-12-19 DOI: 10.11613/bm.2024.010703

Ivana Baršić Lapić, Ivana Baršić Lapić, Lara Milevoj Kopčinović, Nedjeljka Ruljančić, Nedjeljka Ruljančić, Marija Grdić Rajković, Maja Kuštro

引用次数: 0

Detecting the interferences in adrenocorticotropic hormone measurement - three cases reinforcing the efficiency of the complementary clinical and laboratory audit 检测促肾上腺皮质激素测量中的干扰--三个案例强化了临床和实验室互补审计的效率

IF 3.3 3区医学

Biochemia Medica Pub Date : 2023-12-19 DOI: 10.11613/bm.2024.010802

Tugba Barlas, Tugba Barlas, Mehmet Muhittin Yalcin, Zakir Osmanov, Ozlem Gulbahar, Alev Eroglu Altinova, Mujde Akturk, Mehmet Ayhan Karakoc, Ilhan Yetkin, Fusun Balos Toruner

引用次数: 0

Syndrome of inappropriate antidiuretic hormone secretion as an adverse reaction of ciprofloxacin: a case report and literature review 作为环丙沙星不良反应的抗利尿激素分泌失调综合征：病例报告和文献综述

IF 3.3 3区医学

Biochemia Medica Pub Date : 2023-12-19 DOI: 10.11613/bm.2024.010803

Luka Švitek, Luka Švitek, Barbara Grubišić, Barbara Grubišić, Ema Schonberger, Ema Schonberger, Mihaela Zlosa, Mihaela Zlosa, Dario Sabadi, Dario Sabadi, Dario Sabadi, Dubravka Lišnjić, Dubravka Lišnjić, Silvija Canecki-Varžić, Silvija Canecki-Varžić, Ines Bilić-Ćurčić, Ines Bilić-Ćurčić, Sanja Mandić, Sanja Mandić, Sanja Mandić

引用次数: 0

Paraoxonase and arylesterase activity of paraoxonase 1 and oxidative stress parameters in cervical intraepithelial neoplasia 宫颈上皮内瘤变中副氧杂蒽酮酶和副氧杂蒽酮酶 1 的芳基酯酶活性以及氧化应激参数

IF 3.3 3区医学

Biochemia Medica Pub Date : 2023-12-19 DOI: 10.11613/bm.2024.010701

Dražan Butorac, Ivana Ćelap, Ivana Ćelap, Sanja Kačkov Maslać, Tomislav Miletić, Andrea Hulina Tomašković, Petra Turčić, Dubravka Rašić, Ivana Stojanović, Marija Grdić Rajković, Marija Grdić Rajković

引用次数: 0

Potential biomarkers and therapeutic targets for obsessive compulsive disorder: Evidences from clinical studies 强迫症的潜在生物标志物和治疗目标：临床研究证据

IF 3.3 3区医学

Biochemia Medica Pub Date : 2023-12-19 DOI: 10.11613/bm.2024.010503

Aarushi Sultania, Shashank Venkatesan, Dhruv Rishb Batra, Keerthna Rajesh, Rahul Vashishth, Sudesh Ravi, Faraz Ahmad, Faraz Ahmad

引用次数: 0

Diagnostic value and utility of commonly used biomarkers of cardiac and renal function in cardiorenal syndromes: a narrative review. 心肾综合征中常用的心脏和肾脏功能生物标志物的诊断价值和用途:叙述性综述。

IF 3.8 3区医学

Biochemia Medica Pub Date : 2023-10-15 Epub Date: 2023-08-05 DOI: 10.11613/BM.2023.030502

Điđi Delalić, Tanja Brežni, Ingrid Prkačin

{"title":"Diagnostic value and utility of commonly used biomarkers of cardiac and renal function in cardiorenal syndromes: a narrative review.","authors":"Điđi Delalić, Tanja Brežni, Ingrid Prkačin","doi":"10.11613/BM.2023.030502","DOIUrl":"10.11613/BM.2023.030502","url":null,"abstract":"Cardiorenal syndrome (CRS), first defined in 2004 as a consequence of the interactions between the kidneys and other circulatory departments leading to acute heart failure, has since been recognized as a complex clinical entity that is hard to define, diagnose and classify. The framework for the classification of CRS according to pathophysiologic background was laid out in 2008, dividing CRS into five distinct phenotypes. However, determining the timing of individual organ injuries and making a diagnosis of either renal or cardiac failure remains an elusive task. In clinical practice, the diagnosis and phenotyping of CRS is mostly based on using laboratory biomarkers in order to directly or indirectly estimate the degree of end-organ functional decline. Therefore, a well-educated clinician should be aware of the effects that the reduction of renal and cardiac function has on the diagnostic and predictive value and properties of the most commonly used biomarkers (e.g. troponins, N-terminal pro-brain natriuretic peptide, serum creatinine etc). They should also be acquainted, on a basic level, with emerging biomarkers that are specific to either the degree of glomerular integrity (cystatin C) or tubular injury (neutrophil gelatinase-associated lipocalin). This narrative review aims to provide a scoping overview of the different roles that biomarkers play in both the diagnosis of CRS and the prognosis of the disease in patients who have been diagnosed with it, along with highlighting the most important pitfalls in their interpretation in the context of impaired renal and/or cardiac function.","PeriodicalId":9021,"journal":{"name":"Biochemia Medica","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9954832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic challenges of diabetic kidney disease. 糖尿病肾病的诊断挑战。

IF 3.3 3区医学

Biochemia Medica Pub Date : 2023-10-15 Epub Date: 2023-08-05 DOI: 10.11613/BM.2023.030501

Marijana Vučić Lovrenčić, Sandra Božičević, Lea Smirčić Duvnjak

{"title":"Diagnostic challenges of diabetic kidney disease.","authors":"Marijana Vučić Lovrenčić, Sandra Božičević, Lea Smirčić Duvnjak","doi":"10.11613/BM.2023.030501","DOIUrl":"10.11613/BM.2023.030501","url":null,"abstract":"Diabetic kidney disease (DKD) is one of the most common microvascular complications of both type 1 and type 2 diabetes and the most common cause of the end-stage renal disease (ESRD). It has been evidenced that targeted interventions at an early stage of DKD can efficiently prevent or delay the progression of kidney failure and improve patient outcomes. Therefore, regular screening for DKD has become one of the fundamental principles of diabetes care. Long-established biomarkers such as serum-creatinine-based estimates of glomerular filtration rate and albuminuria are currently the cornerstone of diagnosis and risk stratification in routine clinical practice. However, their immanent biological limitations and analytical variations may influence the clinical interpretation of the results. Recently proposed new predictive equations without the variable of race, together with the evidence on better accuracy of combined serum creatinine and cystatin C equations, and both race- and sex-free cystatin C-based equation, have enabled an improvement in the detection of DKD, but also require the harmonization of the recommended laboratory tests, wider availability of cystatin C testing and specific approach in various populations. Considering the complex pathophysiology of DKD, particularly in type 2 diabetes, a panel of biomarkers is needed to classify patients in terms of the rate of disease progression and/or response to specific interventions. With a personalized approach to diagnosis and treatment, in the future, it will be possible to respond to DKD better and enable improved outcomes for numerous patients worldwide.","PeriodicalId":9021,"journal":{"name":"Biochemia Medica","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373061/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9949076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0